Eurofins Scientific, the world leader in food testing services announces that it has acquired Institut Nehring GmbH, a food testing laboratory in the German market. Institut Nehring was established in 1905; today the company is well-known in the German market thanks to its long-history and ... more
Eurofins to acquire EAG LaboratoriesExpanding its presence in North America
Eurofins Scientific announces that it has signed an agreement to acquire EAG Laboratories, a scientific services company providing analytical testing and consulting solutions to a diverse and demanding set of end markets, from Odyssey Investment Partners. The transaction is expected to close in the next few months, subject to the fulfillment of customary closing conditions.
EAG is headquartered in San Diego and has 21 laboratories in 18 locations worldwide, serving approximately 4000 customers with revenue generated from more than 50 countries. It believes it is the largest independent US-centric platform in the testing, inspection and certification (TIC) market, and is a highly differentiated player in high-science analytical testing and consulting solutions. EAG serves three main markets, namely Material and Engineering Sciences, Agroscience and Biopharmaceuticals. The company has grown significantly over its 40-year history, both organically and through acquisitions.
Today EAG employs over 1000 highly educated and talented scientists and support personnel, and expects to generate revenues in excess of US$ 220m in 2017, with an EBITDA margin close to 30%. The agreed acquisition price is US$780m on a cash free debt free basis. As Eurofins and EAG have almost no geographic overlap, no site consolidations or restructuring costs are foreseen as a result of this acquisition. Synergetic top line market effects are expected in Agroscience and Biopharmaceuticals products testing based on cross selling to each organization’s clients in the other company’s geographic base. Based on EAG’s historic and projected profitability, the transaction should be immediately margin accretive for Eurofins after closing.
EAG provides Eurofins an entry into the dynamic and growing Materials and Engineering Sciences markets, where EAG is number one in its core markets. This represents an entirely new business line for Eurofins, and provides a platform with significant organic and inorganic growth potential. The company provides highly advanced investigative testing of organic and inorganic materials, serving a wide range of industries including high tech, aerospace, defense, medical device, chemicals and semiconductors. Services include elemental profiling, advanced imaging, materials characterization, metallurgy and failure analysis. EAG differentiates itself with proprietary testing systems, software and processes, market leading capacity and turnaround time, as well as deep technical knowledge and expertise.
EAG is also a leading North American provider of advanced chemical testing services for pesticides, industrial and household chemicals, an area where Eurofins had little presence so far in the USA. It provides end-to-end support for e-fate, metabolism, eco-toxicology and residue studies required for pesticide and chemical regulatory testing to support global registration requirements. The company has extensive expertise to test molecules with highly complex profiles. EAG’s agroscience business is highly complementary to the existing Eurofins agroscience business in terms of capabilities/capacities and particularly geography.
In the biopharmaceutical testing market, EAG adds a highly desirable asset to the Eurofins BioPharma Product Testing group in a geographic area of the USA where Eurofins had no presence so far. EAG’s laboratory in Missouri provides an extensive range of small molecule and biologics testing and characterization services to a broad range of biopharmaceutical customers. The company provides advanced testing and scientific support services from a well-equipped and state-of-the-art facility. EAG supports biopharmaceutical, generic and biosimilar customers from the research and development phase through to commercialization.
Comment from Dr. Gilles Martin, Eurofins CEO: “We are extremely pleased to welcome EAG and its talented teams to the Eurofins Group. EAG’s competencies, reputation for scientific excellence and footprint further strengthen Eurofins’ global offering in the highly attractive biopharmaceutical and agroscience testing markets with perfect geographic complementarity. In addition EAG provides Eurofins with an entirely new business line and growth market in material sciences. We look forward to strengthening their portfolio and operating footprint by providing access to the full range of services and capabilities of the Group.”
- testing services
- household chemicals
Eurofins Scientific announces that it has signed an agreement to acquire the Forensics and Security division of LGC (“LGC Forensics”), the largest player in the UK forensics market, a European pioneer in this field and a significant forensic DNA testing provider in Germany, from LGC Group. ... more
Eurofins Scientific announces that it has signed an exclusive agreement with Tata Group to acquire Advinus Therapeutics, a preclinical and clinical phase contract research company for Safety Assessment, DMPK, CMC services, and Analytical R&D Services. The transaction is expected to close in ... more
- 1Mechanism involved in novel drug design with potential to treat tuberculosis
- 2Nanoscale virus features reconstructed from correlations of scattered X-rays
- 3New antibiotic resistance genes found
- 4Neutrons observe vitamin B6-dependent enzyme activity useful for drug development
- 5Eurofins acquires food testing laboratory Institut Nehring
- 6A detailed look at 2-D structure of turbulence in tokamaks
- 7Pioneering discovery of an odor-detecting receptor enhancer
- 8How rough microparticles can cause big problems
- 9Initiative taps scientists to create atlas of cells in human spinal cord
- 10Proteins may prevent dysfunction and disease by relaxing
- Integrated lab-on-a-chip uses smartphone to quickly detect multiple pathogens
- Explaining how UV rays trigger skin cancer
- Neutrons observe vitamin B6-dependent enzyme activity useful for drug development
- Initiative taps scientists to create atlas of cells in human spinal cord
- Proteins may prevent dysfunction and disease by relaxing